Lilly's COVID-19 Science Leads to a Second FDA Emergency Use Authorization

Eli Lilly and Company  | November 19, 2020

This guest article comes from Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly.

After artificial intelligence technology raised a hypothesis that prompted interest in studying Lilly’s existing rheumatoid arthritis medicine for COVID-19, we quickly mobilized our network of collaborators, scientists and clinical trial experts to understand the medicine’s potential in treating the novel coronavirus.

Over the course of more than nine months, our teams have worked tirelessly. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), chose to study our medicine in hospitalized patients at risk for serious outcomes. We also initiated our own clinical trial.

We have now taken another important step forward, as the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the medicine’s use as part of a combination therapy. This authorization allows us to make the treatment available for hospitalized patients with COVID-19 that require oxygen. It is the second EUA issued for a Lilly medicine.

We could not have come this far, this quickly, without the ongoing commitment of everyone involved and the unprecedented collaboration of scientists and regulators.

I am proud to be part of a company that has risen to the challenge in the fight against COVID-19 and continues working to help patients with the greatest need.